cihr and frq have decided to support canadian investigators on a large-scale, interdisciplinary, international brain research initiative. understanding how behavior emerges from the dynamic patterns of electrical and chemical activity of brain circuits is universally recognized as one of the great, unsolved mysteries of science. advances in recent decades have elucidated how individual elements of the nervous system and brain relate to specific behaviors and cognitive processes. however, there remains much to discover to attain a comprehensive understanding of how the healthy brain functions, specifically, the general principles underlying how cognition and behavior relate to the brain’s structural organization and dynamic activities, how the brain interacts with its environment, and how brains maintain their functionality over time.

as part of the brain research through advancing innovative neurotechnologies (brain) initiative in the united states, the us national science foundation (nsf) has developed the next generation networks for neuroscience (neuronex). the objective of the neuronex program is the establishment of distributed, international research networks that build on existing global investments in neurotechnologies to address overarching questions in neuroscience. the creation of such global research networks of excellence will foster international cooperation by seeding close interactions between a wide array of organizations across the world, as well as creating links and articulating alliances between multiple recently launched international brain projects. canadian researchers are well placed to provide a leadership role within neuronex networks.

the goal of the neuronex technology-enabled, team-based neuroscience solicitation is to support collaborative networks comprised of international teams of disciplinarily-diverse researchers working on a common foundational question in neuroscience. each network will be organized around a central theme identified by the participants. individual networks will be composed of 2 to 4 interdisciplinary research groups (irgs), each consisting of about 3 to 6 investigators. each irg will have a defined intellectual role that fits within the overall research goal of the network. it is envisaged that the composition of each irg may cut across organizations and countries, as appropriate. through this funding opportunity, cihr and frq will support canadian investigators on neuronex irgs.

research areas

a network must be composed of international teams (irgs) that include disciplinarily-diverse experimentalists and theorists working to obtain mechanistic insights into foundational questions in neuroscience. these networks must incorporate:

• strong integration across levels of study within an organism
• comparative analysis of neural underpinnings of behavior in naturalistic settings
• predictive theory and modeling to guide research and uncover general principles
• global partnerships

the indigenous health nursing chair initiative is expected to:

• support research and development of knowledge and best and wise practices in the area of indigenous health nursing
• investigate structural factors, including gender, that support and impede indigenous health nursing and indigenous health
• explore, describe and/or explain indigenous research paradigms and their theoretical and methodological implications for indigenous health nursing standards
• advance the understanding and conceptualization of indigenous health nursing and its role in the nursing profession
• examine the recruitment and retention of people into the nursing discipline (i.e., practice, education, research and administration) and nurses into the specialty of indigenous health nursing
• create opportunities and the will for nurses and trainees to engage in indigenous health nursing leadership
• provide mentorship and training for 世界杯2022赛程表淘汰赛

as stated in cihr's strategic plan, health research roadmap ii: capturing innovation to produce better health and health care for canadians, cihr wants to seize the momentum and contribute to innovative, evidence-informed ehealth solutions that will improve patient experiences, health outcomes and the sustainability of the health care system, as well as engage with the international community. as a way of expanding the opportunities for funding and engagement in international markets for ideas and industries, this program enables cihr to leverage the value of its funding investments by participating in transnational joint calls in ehealth research.  

this funding opportunity lies within the scope of the international component of cihr's ehealth innovations initiative (ehii). the active and assisted living programme (aal) provides canada with an established and successful mechanism to foster international collaborations and offers the opportunity to engage diverse communities in generating transformative ehealth solutions.

the aal programme is a common funding activity of member states of the aal association, with the financial support of the european commission, based on article 185 of the treaty on the functioning of the european union. the aal programme calls are complementary to the horizon 2020 calls related to active and healthy ageing under societal challenge 1 (sc1), as well as to the horizon 2020 2018-2020 work programme on information and communication technologies [ pdf (1190 kb) - external link ].

the aim of the aal programme is to provide innovative information and communication technologies (ict) based solutions including products, systems or services. these solutions aim to enhance older adults' quality of life, to improve the long-term sustainability of the health and long-term care systems and to strengthen the industrial base in europe and internationally. the main goal is to improve the autonomy, participation in social life, skills, and employability of older adults.

the challenge-led call for proposals aal 2019: sustainable smart solutions for ageing well is part of the aal programme that was approved in may 2014 by the european parliament and the council of the european union.

the aal call 2019 is open to collaborative projects developing ict-based solutions targeting any application area(s) within the aal domain, with a focus on specified markets (consult aal website for more information on different markets). the solutions need to be embedded into the strategies of the participating end-user organizations, service providers and business partners. the wishes and aspirations of older adults in combination with the demands from the other stakeholders involved – e.g. providers and payers - will have a critical role in shaping useful and attractive aal solutions with a high market potential.

although the aal call 2019 is supporting two types of projects, cihr will only be funding collaborative projects:

• collaborative projects are multi-annual projects that are expected to be user-driven through co-creation and address a specified challenge. furthermore, the route to market needs to be clearly described and aligned with the business strategies of the partners responsible for commercialisation. collaborative projects (carried out by consortia composed of at least 3 organisations from 3 different countries including an end user organisation and a business partner) are the main funding tools for this call. this type of project has a duration of 18 to 36 months with maximum funding of €2.500.000.

for more information, and the full call text please consult the active and assisted living website.

concussion is recognized as a serious public health epidemic, particularly in children, where rates have doubled over the last decade, with an estimated 750,000 pediatric acute concussion visits to emergency departments (eds) occurring annually in the united states alone. while many children experience symptom resolution within 2 weeks, approximately 33% experience ongoing cognitive, somatic, psychological, behavioural symptoms, or a combination of these symptoms, known as “persistent post-concussive symptoms, or ppcs”.

in 2012 canada (through cihr) became one of three founding countries in the “international initiative for tbi research (intbir), along with the european union (eu health directorate) and the united states (nih-ninds). as part of the executive leadership in intbir, the institute of neurosciences, mental health and addiction (cihr-inmha) and partners launched $10m worth of funding opportunities including five team grants in pediatric concussion. in march 2016 one of these teams, led by roger zemek, published the first clinical prediction tool to identify children at risk of ppcs) given the leadership role of canadian researchers in concussion, cihr-inmha was approached by its intbir partner nih-ninds to participate on this new bilateral funding opportunity.

this funding opportunity represents the next step of the continuing canadian and american investments into pediatric concussion research, care, and knowledge exchange.

for more information, please consult the nih call. (updated: 2019-03-22)

the fy19 defense appropriation provides $90 million (m) to the u.s. department of defense peer reviewed cancer research program (prcrp) to support innovative, high-impact cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 prcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

congressionally directed topic areas:  to be considered for funding, applications for the fy19 prcrp must address at least one of the topic areas as directed by congress.  research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted.

the fy19 prcrp topic areas are:

*the definition of adolescents and young adults is derived from the national cancer institute (https://www.cancer.gov/types/aya) and can be considered to be people between 15 and 39 years of age.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s). research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^†as derived from the national cancer institute dictionary of cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

^ǂrare cancer is defined by the national cancer institute as a cancer that occurs in fewer than 15 out of 100,000 people each year.  cancers studied under this topic area should be within the scope of the congressional language and the intent of the program announcement(s).

the fy19 prcrp military relevance focus areas are listed below:

it is central to the vision and mission of the prcrp that applications address how the proposed research is related to military health and mission readiness of both deployed and non-deployed personnel, their dependents, retirees, and veterans. the fy19 prcrp requires all applications to respond to at least one of military relevance focus areas listed below:

• militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
• gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, veterans, their beneficiaries, and the general public

https://cdmrp.army.mil/funding/prcrp

career development award – letter of intent due august 21, 2019

principal investigator (pi): independent investigator within 10 years of completing terminal degree (excluding time spent in medical residency, clinical training, or on family medical leave) by the time of the application submission; time spent as a postdoctoral fellow is not excluded.

postdoctoral fellows are not eligible.

career guide: investigators at or above the level of associate professor (or equivalent); must have a proven publication and funding record in cancer research. 

the pi and the career guide do not need to be located at the same organization.\

• ·         letter of intent is required.  an invitation to submit a full application is not required.
• ·         supports independent, early-career investigators to conduct impactful research, together with the guidance of an experienced cancer researcher.
• ·         must address at least one of the fy19 prcrp topic areas.
• ·         must address at least one of the fy19 prcrp military relevance focus areas.
• ·         preliminary data are not required.
• ·         clinical trials are not allowed.
• ·       maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.

horizon award – letter of intent due august 21, 2019

principal investigator (pi):

predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her mentor’s laboratory application submission deadline.

or

postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her mentor’s laboratory at application submission deadline.

mentor: investigators at or above the level of assistant professor (or equivalent); must have a proven publication and funding record in cancer research. 

pi and mentor must be at the same organization.

• ·         letter of intent is required.  an invitation to submit a full application is not required.
• ·         supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., mentor).
• ·         must address at least one of the fy19 prcrp topic areas.
• ·         must address at least one of the fy19 prcrp military relevance focus areas.
• ·         preliminary data are not required.
• ·         clinical trials are not allowed.
• ·       maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 2 years.

idea award with special focus –preproposal due may 22, 2019

independent investigator with a faculty-level appointment (or equivalent).

• ·         preproposal is required; application submission is by invitation only.
• ·         supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to service members, veterans, military beneficiaries, and the american public.
• ·         emphasis on innovation and military relevance/impact.
• ·         must address at least one of the fy19 prcrp topic areas.
• ·         must address at least one of the fy19 prcrp military relevance focus areas.
• ·         inclusion of preliminary data are not required.
• ·         clinical trials are not allowed.
• ·       maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 2 years.

impact award – preproposal due may 22, 2019

independent investigators at or above the level of assistant professor (or equivalent).

only one pre-application per pi is allowed.

• ·         preproposal is required; application submission is by invitation only.
• ·         supports hypothesis-driven, high impact research.
• ·         encourages applications that support the ideas that specifically focus on critical scientific and clinical cancer issues.
• ·         emphasis on impact, transformation, and continuity of research.
• ·         must address at least one of the fy19 prcrp topic areas.
• ·         must address at least one of the fy19 prcrp military relevance focus areas.
• ·         preliminary data are required.
• ·         clinical trials are allowed.
• ·       maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.

translational team science award – preproposal due may 22, 2019

at least two and up to three pis must partner in one overarching correlative or translational research study in at least one of the required fy19 prcrp topic areas.

the pis must be at or above the level of assistant professor or equivalent.

• ·         preproposal is required; application submission is by invitation only.
• ·         emphasizes multi-pi, multidisciplinary collaborations.
• ·         supports hypothesis-driven translational studies that are associated with an ongoing or completed clinical trial and are focused on research for the next-phase clinical research.
• ·         must address at least one of the fy19 prcrp topic areas.
• ·         must address at least one of the fy19 prcrp military relevance focus areas.
• ·         encourages research in interventions to improve the quality of life, cancer prevention, and metastasis.
• ·         preliminary data are required.
• ·         clinical trials are allowed.
• ·       maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 4 years.

a pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507 
help@ebrap.org

the canadian institutes of health research institute of cancer research (icr) and institute of neurosciences, mental health and addiction (inmha), in partnership with the canadian cancer society, will support research investigating the benefits and/or harms related to therapeutic use of cannabis in people living with cancer.

the cannabis research in priority areas team grants is expected to:

• ·         generate new scientific knowledge that will advance our understanding of the potential benefits and/or harms of cannabis and/or cannabis use, and impact policies and programs in this area
• ·         encourage interdisciplinary collaborations, including from across health research and from domains outside of health research, and the sharing of data and resources
• ·         enhancing capacity development and training in cannabis research
• ·         connect to existing knowledge translation efforts across canada, for example through mhcc or the canadian centre on substance use and addiction (ccsa)

the maximum amount per grant is $300,000 per year for up to 5 years for a total of $1.5 million, per grant. $1.5 million is available to fund an application relevant to the cancer pool (sponsored by the canadian cancer society, icr, and inmha).

loi due date: may 15, 2019

loi notice of decision: july 15, 2019

full application deadline: october 8, 2019

funding start date: january 1, 2020

all applications must be submitted through cihr’s researchnet. for more information view the funding opportunity details on the cihr website.

*cihr will be hosting webinar(s) to review with participants the requirements of this funding opportunity and to answer questions. to find out more information and to register, visit the webinars page.*

the fy19 defense appropriation provides $7.5 million (m) to the department of defense autism research program (arp) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program research, development, test, and evaluation appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 arp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

https://cdmrp.army.mil/funding/arp

clinical trial award – preapplication due may 1, 2019

• investigators at or above the level of associate professor (or equivalent), or

• ·         early-career investigator partnering pi option: investigators at or above the level of associate professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:

o   must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline

o   is no more than 7 years from the receipt of a terminal degree

• has the freedom to commit at least 50% time to the project

• ·         supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (asd).
• ·         applications in the following areas are strongly encouraged:

o   behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.

o   pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.

o   dissemination/implementation of clinically validated interventions.

o   improve diagnosis and access to services across the life span.

o   interventions promoting success in key transitions to adulthood for individuals living with asd.

o   healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).

o   cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.

• ·         preliminary data relevant to the proposed clinical trial are required.
• ·         pre-application is required; application submission is by invitation only.
• ·         the maximum funding for the entire period of performance is $1,000,000 in direct costs (plus indirect costs).
• ·         the maximum period of performance is 4 years.
• ·         early-career investigator partnering pi option:
• ·         the maximum period of performance is 4 years.
• ·         the maximum allowable funding for the entire period of performance is f $1,155,000 for direct costs (plus indirect costs).

• early-career investigator partnering pi option supports the development of young investigators .pursuing or wishing to pursue a career in asd clinical trial research.

clinical translational research award – preapplication due may 1, 2019

• investigators at or above the level of assistant professor (or equivalent)

• ·         supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of asd.
• ·         applications in the following areas are strongly encouraged:

o   behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.

o   pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.

o   dissemination/implementation of clinically validated interventions.

o   improve diagnosis and access to services across the life span.

o   interventions promoting success in key transitions to adulthood for individuals living with asd.

o   healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).

o   cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.

• ·         preliminary data relevant to the proposed project are required.
• ·         the maximum allowable funding for the entire period of performance is $500,000 in direct costs (plus indirect costs).

• pre-application is required; application submission is by invitation only.

• maximum period of performance is 3 years

idea development award – preapplication due may1, 2019

• ·         investigators at or above the level of assistant professor (or equivalent), or
• ·         supports the development of innovative, high-impact ideas that advance the understanding of asd and ultimately lead to improved outcomes. 
• ·         applications in the following areas are strongly encouraged:

• multiple pi option:  
  up to two investigators may collaborate on a single application, each of whom will be recognized as a principal investigator (pi) and receive a separate award. 

o   assessment of novel therapeutics using valid preclinical models.

o   environmental risk factors.

o   mechanisms of heterogeneous clinical expression of asd.

o   mechanisms underlying conditions co-occurring with asd (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures, eating disorders, pharmacological side effects, gender dysphoria).

o   factors promoting success in key transitions to inde78pence for individuals living with asd.

o   factors impacting quality of life during geographic relocation, such as military permanent change of station.

o   development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the lifespan and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief).

o   improve diagnosis and access to services across the life span.

o   cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services.

o   long-term treatment outcomes from previous clinical trials for asd core symptoms or to alleviate co-occurring conditions.

• ·         preliminary data are required.
• ·         pre-application is required; application submission is by invitation only.
• ·         maximum funding of $500,000 for direct costs (plus indirect costs)

• clinical trials or applications including a clinical trial aim are not allowed.

• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507 
help@ebrap.org

the fy19 defense appropriations act provides $15 million (m) to the department of defense neurofibromatosis research program (nfrp) to support innovative, high-impact nf research.  applications to the fy19 nfrp are being solicited by the u.s. army medical research acquisition activity (usamraa).  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

https://cdmrp.army.mil/funding/nfrp

areas of emphasis: the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy19 areas of emphasis.  not all areas of emphasis are applicable to each award mechanism offered by the fy19 nfrp.  if the proposed research project does not address one of the fy19 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided.

• ·         health services research

–         evidence-based best clinical practices

• §  outcomes of specific therapies, including surgery and radiation therapy

–         implementation and access to nf-specific healthcare

–         utilization of technology and informatics

• ·         heterogeneity of nf-related tumors
• ·         non-tumor manifestations

–         cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations

• ·         novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

–         transition from benign to malignant

• ·         nutritional, environmental, and other modifiers of nf
• ·         preclinical efficacy studies
• ·         target identification, drug discovery
• ·         targeted immunotherapies

clinical trial award – letter of intent due may 23, 2019

must be at or above the level of assistant professor (or equivalent).

• ·         supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (nf)
• ·         funds phase 0, i, or ii clinical trials relevant to nf and/or schwannomatosis.  combinations of phases are permitted.
• ·         funding must support a clinical trial and may not be used for preclinical studies.
• ·         scientific rationale and preliminary data required for phase i, ii clinical trial applications.
• ·       maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 for direct costs if requesting the qualified collaborator option).
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·       maximum period of performance is 4 years

exploration – hypothesis development award – letter of intent due may 23, 2019

investigators at all academic levels (or equivalent)

• ·         supports the initial exploration of innovative, high-risk, high-gain concepts in nf research.
• ·         preliminary and/or published data encouraged but not required.
• ·         projects involving human subjects or human anatomical substances must be exempt under 32 cfr 219.104(d) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.
• ·         clinical trials not allowed.
• ·       the maximum allowable funding for the entire period of performance is of $100,000 in direct costs.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·       maximum period of performance is 2 years

new investigator award – letter of intent due may 23, 2019

must be either:

an independent investigator at or below the level of assistant professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project; or

an established investigator in an area other than nf at or above the level of assistant professor seeking to transition into a career in nf research and must plan to commit at least 10% of his/her effort toward the proposed research project.

to be eligible, applicants may not have received more than $300,000 in direct costs for nf research as a principal investigator of one or more federally funded, non-mentored peer reviewed grants.

• ·       supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of nf research.
• ·       prior experience in nf research is not required.
• ·       preliminary and/or published data relevant to nf and the proposed research project is required.
• ·       clinical trials not allowed
  • ·      the maximum allowable funding for the entire period of performance is $450,000 in direct costs.
  • ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·      maximum period of performance is 3 years

early investigator research award – letter of intent due may 23, 209

the investigator must:

be involved in postdoctoral training or medical residency program; and

possess at least 1 and up to 4 years of continuous postdoctoral research experience by the early investigator research award application submission deadline; and

possess a clinical doctoral degree (i.e., ph.d., m.d. /ph.d., d.o. /ph.d.) or a clinical doctoral degree (i.e., m.d. /d.o. or ph.d. in a clinical discipline) from an accredited organization or program.

• ·      supports nf-focused research opportunities for individuals in the early stages of their careers.
• ·      investigators must have a designated mentor who is an experienced nf researcher.
• ·      the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
• ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·      maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism is also found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507 
help@ebrap.org